Why is "AIM ImmunoTech" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-08 08:11:05
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
AIM_ImmunoTech entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-04-08 and was most recently seen on 2026-04-08.
Wikipedia Overview
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - Yahoo Finance
-
AIM ImmunoTech Converts ~$450,000 of Note Into 1.92M Shares in Exchanges With Streeterville - tradingview.com
-
AIM ImmunoTech Extends IP Protection for Ampligen Through 2039 with Broad US Patent - Contract Pharma
-
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - GlobeNewswire
-
AIM ImmunoTech doses final patient in pancreatic cancer trial - Stock Titan
-
AIM ImmunoTech Secures European and U.K. Patent Protection for Ampligen in Long COVID Through 2041 - Quiver Quantitative
-
Biodefense is force protection: Ready today, prepared for tomorrow - Breaking Defense
-
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - Yahoo Finance
-
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod - GlobeNewswire
-
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical - Yahoo Finance
-
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules - GlobeNewswire
-
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - Yahoo Finance
-
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer - Yahoo Finance
-
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - Yahoo Finance
-
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - Yahoo Finance
-
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities - GlobeNewswire
-
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - GlobeNewswire
-
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - GlobeNewswire
-
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment - GlobeNewswire
-
AIM ImmunoTech Secures Ampligen Patent Protection in Europe - Intellectia AI
-
AIM ImmunoTech Reports Completion of Phase 2 Ampligen Dosing in Metastatic Pancreatic Cancer Trial, Advances Phase 3 Planning - Quiver Quantitative
-
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - GlobeNewswire
-
AIM ImmunoTech outlines pancreatic cancer trial milestones - Investing.com
-
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP - Yahoo Finance
-
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Yahoo Finance
-
AIM ImmunoTech Announces Emerging Ebola Opportunity for - GlobeNewswire
-
AIM ImmunoTech Announces Agreement to Exercise Existing Warrants for $4.2 Million in Gross Proceeds - Quiver Quantitative
-
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) - GlobeNewswire
-
AIM - Finviz
-
AIM ImmunoTech CEO Urges Biodefense Military Integration - The Globe and Mail
-
Japan clears cancer patent pairing AIM’s Ampligen with checkpoint inhibitor drugs - Stock Titan
-
AIM ImmunoTech Releases Q2 2026 Financial Results - news.alphastreet.com
-
AIM ImmunoTech raises $2.65M in direct offering - Investing.com
-
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - The Manila Times
-
AIM ImmunoTech (AIM) Advances Enrollment in Pancreatic Cancer Tr - GuruFocus
-
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules - tradingview.com
-
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - Stocktwits
-
AIM ImmunoTech Expands Cancer Drug Trials with Key Collaboration - StocksToTrade
-
AIM ImmunoTech Engages Thermo Fisher’s PPD for Phase 3 Cancer Trial - timothysykes.com
-
AIM ImmunoTech Inc. (AIM) Key Financial Ratios – Valuation, Profitability & More - Value Research
-
Why Did AIM Stock Plummet 35% Today? - Stocktwits
-
AIM | AIM ImmunoTech Inc. Financials - Income Statement - Quiver Quantitative
-
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer - The Manila Times
-
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - Bitget
-
Should I Buy AIM? AIM 2026 Analysis - Intellectia AI™ - Intellectia AI
-
AIM ImmunoTech highlights Ampligen's potential as early Ebola treatment amid WHO emergency declaration. - Pluang
-
Form 8K AIM ImmunoTech Inc For: 6 August By Investing.com - Investing.com India
-
$AIM ImmunoTech (AIM.US)$ easiest money i ever made $Soligenix (SNGX.US)$ you 2 booboo - Moomoo
-
AIM ImmunoTech Eliminates $1.22 Million Debt via Stock Exchange - Minichart
-
AIM ImmunoTech Q1 2026 Earnings: EPS Misses Estimates as Company Continues Clinical Development - Forward Guidance Trends - vinanet.vn
-
AIM ImmunoTech (AIM) Climbs 7.98% as Biotech Micro-Cap Tests Key Resistance at $0.29 - Catalyst Driven Stocks - vinanet.vn
-
AIM ImmunoTech Q2 2026 Earnings: EPS Misses by Wide Margin as Shares Drop Sharply - Earnings Miss Streak - vinanet.vn
-
AIM ImmunoTech to present at Webull Corporate Connect Webinar Series - scanx.trade
-
AIM ImmunoTech Hovers Near Flat as Stock Consolidates at $0.25 - Low Beta Factor - vinanet.vn
-
AIM ImmunoTech (AIM) Stock Price, News & Analysis $AIM - MarketBeat
-
AIM ImmunoTech Provides Routine Update on Annual Filings - Bitget
-
AIM ImmunoTech highlights pancreatic cancer program momentum - scanx.trade
-
AIM ImmunoTech Q1 2026 Earnings: Wider-than-Expected Loss Highlights R&D Spending Amid Ongoing Pipeline Progress - New Analyst Coverage - vinanet.vn
-
AIM ImmunoTech Provides Routine Update on Annual Filings - The Manila Times
-
AIM ImmunoTech Q1 2026 Earnings: Loss Widens 52.5% Past Estimates; Shares Rally 8.09% - Earnings Turnaround - vinanet.vn
-
AIM ImmunoTech advances pancreatic cancer program to pivotal stage - scanx.trade
-
AIM ImmunoTech prices $2.65 million financing at-the-market - scanx.trade
-
AIM ImmunoTech Q1 2026 Earnings: Loss Widens 52.5% Past Estimates; Shares Rally 8.09% - Guidance Accuracy Score - siam.in
-
AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer - Clinical Trials Arena
-
AIM ImmunoTech Q2 2026 Earnings: EPS Misses by Wide Margin as Shares Drop Sharply - Interim Report - dars.gov.et
-
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split - Yahoo Finance
-
Aim Immunotech (AIM) Stock Price, News & Analysis - Stock Titan
-
AIM ImmunoTech (AIM) Plunges 20%: Support Tested at $0.39 as Selling Pressure Intensifies - Advance Decline Volume - dars.gov.et
-
AIM ImmunoTech Q1 2026 Earnings: Wider-than-Expected Loss on Absence of Revenue - Revenue Recognition Risk - dars.gov.et
-
AIM ImmunoTech Q1 2026 Earnings: EPS Misses Estimates Amid Continued R&D Focus - Margin Expansion Trends - dars.gov.et
-
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - Yahoo Finance
-
AIM ImmunoTech concludes dosing in Phase II post-Covid drug trial - Clinical Trials Arena
-
AIM ImmunoTech Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Declines - Energy Earnings Report - dars.gov.et
-
AIM ImmunoTech CEO to Share Company Updates at Webull's Biotech Investment Series - Stock Titan
-
Aim Immunotech CEO Thomas Equels acquires $823 in common stock - Investing.com
-
Ted Kellner's multimillion-dollar fight to unseat pharma firm's board - The Business Journals
-
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com
-
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment - Yahoo Finance
-
Ted Kellner low-key on joining pharma firm board he fought to join - The Business Journals
-
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - GlobeNewswire
-
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research - Yahoo Finance
-
Aim Immunotech CEO Thomas K Equels buys $5,060 in common stock - Investing.com
-
AIM ImmunoTech reports positive Phase III Ampligen data in long Covid - Clinical Trials Arena
-
AIM ImmunoTech shifts director pay to stock for cash conservation - Investing.com
-
AIM ImmunoTech reports positive safety data from Covid-19 trial - Clinical Trials Arena
-
AIM ImmunoTech reports positive data from intranasal Covid-19 trial - Clinical Trials Arena
-
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. As Scientific Officer - citybiz
-
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., As Chairman Of Its Scientific Advisory Board - citybiz
-
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease - Yahoo Finance
-
AIM ImmunoTech (AIM) Fundamental & Financial Data - Stocktwits
-
AIM ImmunoTech Enters into Pancreatic Cancer Clinical - GlobeNewswire
-
AIM ImmunoTech – Ampligen® (rintatolimod) - Genetic Engineering and Biotechnology News
-
AIM ImmunoTech (AIM) Stock News & Updates - Stock Titan
-
AIM Forecast — Price Prediction for 2026. Should I Buy AIM? - Intellectia AI
-
AIM ImmunoTech Inc. (AMEX:AIM) - intelligentinvestor.com.au
-
AIM ImmunoTech (AIM) sentiment score, message volume, participation score and buzz level - Stocktwits
-
AIM ImmunoTech says data from the ongoing Phase 2 ovarian cancer clinical study utilizing Ampligen accepted for presentation at AACR 2022 Annual Meeting - Proactive financial news
-
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering - The Manila Times
-
AIM ImmunoTech receives required Ethics Committee approval in the Netherlands to commence its Phase 1 clinical study for Ampligen as an intranasal therapy - Proactive financial news
-
AIM ImmunoTech gets approval to include long-term COVID-19 patients with chronic fatigue in Ampligen clinical trial - Proactive financial news
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.